Reducing disparities in medication use: Responding to managed care pharmacy's imperatives [0.03%]
减少用药差异：应对管理护理药房的要求
Susan A Cantrell
Susan A Cantrell
Although disparities and inequities in health status and access to health care services have long existed in our nation, the COVID-19 pandemic cast a bright spotlight on them. Communities of color and socioeconomically disadvantaged populat...
Racial and social inequities in medication use: A review of articles responding to the Journal of Managed Care + Specialty Pharmacy's Call to Action [0.03%]
用药方面的种族和社会不平等：对《 managed care & specialty pharmacy》杂志呼吁行动的响应性文章回顾
Anna Hung,Lixian Zhong,Prabashni Reddy
Anna Hung
This article provides a summary of Viewpoint and Research articles responding to the 2020 Journal of Managed Care + Specialty Pharmacy Call to Action to address racial and social inequities in medication use. We find great heterogeneity in ...
Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non-small cell lung cancer [0.03%]
大Panel下一代测序在非鳞状细胞晚期非小细胞肺癌一线治疗决策中的性价比研究
Ibrahim M Abbass,Daniel M Sheinson,Anuj Shah et al.
Ibrahim M Abbass et al.
Background: Clinical practice guidelines recommend broad-panel genomic profiling to identify actionable genomic alterations for patients with advanced non-small cell lung cancer (aNSCLC). ...
Clinical and economic evaluation of tralokinumab for atopic dermatitis [0.03%]
杜拉利尤单抗治疗特应性皮炎的临床和经济评价
Ryan A Moreau,Angela Y Su,Molly M Csere et al.
Ryan A Moreau et al.
Tralokinumab is the first selective interleukin 13 inhibitor approved for moderate to severe atopic dermatitis. This article reports the findings of a comprehensive literature review and extensive economic analysis to assess tralokinumab's ...
Affordability and adherence gains for Medicare Part D low-income subsidy recipients when low-income subsidy benefits expanded in 2024 [0.03%]
2024年低收入补贴受益扩大后，Medicare Part D低收入补贴领取者的可负担性和依从性提高
Bruce C Stuart,F Ellen Loh,J Samantha Dougherty
Bruce C Stuart
Background: The lowest-income beneficiaries enrolled in the Medicare Part D prescription drug program receive "full subsidies" that waive the premium and deductible and impose minimal copayments. Those with slightly highe...
Cheaper is not always better: Drug shortages in the United States and a value-based solution to alleviate them [0.03%]
便宜没好货：美国的药品短缺和一种基于价值的方法来解决这一问题
Inmaculada Hernandez,Sean D Sullivan,Ryan N Hansen et al.
Inmaculada Hernandez et al.
Drug shortages threaten patients' access to medications and are associated with adverse health outcomes and increased costs. Drug shortages disproportionately occur among generic drugs of limited profitability, most notably drugs administer...
Real-world clinical and economic outcomes for patients with advanced non-small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy [0.03%]
基于液体活检全面基因组检测的晚期非小细胞肺癌患者真实世界临床及经济效益研究
Julie A Wiedower,Shaun P Forbes,L Jill Tsai et al.
Julie A Wiedower et al.
Background: Oncology clinical trial enrollment is strongly recommended for patients with cancer who are not eligible for established and approved therapies. Many trials are specific to biomarker-targeted therapies, which ...
Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers [0.03%]
NTRK融合阳性实体肿瘤患者的临床特征和治疗模式：美国学术癌症中心的多中心队列研究
Connor Willis,Trang Au,Andre Hejazi et al.
Connor Willis et al.
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare oncogenic drivers prevalent in 0.3% of solid tumors. They are most common in salivary gland cancer (2.6%), thyroid cancer (1.6%), and soft-tis...
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States [0.03%]
美国转移性雄激素敏感型至雄激素非敏感型前列腺癌的疾病进展治疗后的实际经济负担
Deborah R Kaye,Ibrahim Khilfeh,Erik Muser et al.
Deborah R Kaye et al.
Background: The advent of next-generation imaging will likely reduce nonmetastatic prostate cancer (PC) prevalence and increase identification of metastatic prostate cancer cases, resulting in two predominant advanced sta...
Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B [0.03%]
评估医疗补助受益者用于血友病B的凝血因子IX预防治疗的卫生资源使用、结果和成本
Nathan Pauly,Anita Burrell,Douglass Drelich et al.
Nathan Pauly et al.
Background: Hemophilia B is characterized by a deficiency of clotting factor IX (FIX), leading to excessive bleeding. Hemophilia B is commonly treated using replacement FIX therapy, which may be administered prophylactica...